Oric Pharmaceuticals (ORIC) 2024 Wells Fargo Healthcare Conference summary

Company overview and strategy

• Focuses on overcoming resistance in cancer, targeting prostate, lung, and breast cancers with a two-pronged approach: internal R&D and opportunistic business development.

• Two lead clinical programs: ORIC-114 (brain-penetrant EGFR/HER2 exon 20 inhibitor) and ORIC-944 (allosteric PRC2 inhibitor for prostate cancer).

• Pipeline prioritization is based on strategic fit and market opportunity, with ongoing evaluation of new in-licensing opportunities.

• Prepared to independently advance registrational studies but open to strategic partnerships if advantageous.

• Ended Q2 with $309 million in cash, providing runway into late 2026, supporting planned registrational studies.

ORIC-114 clinical development

• Designed as a brain-penetrant EGFR exon 20 inhibitor, allowing inclusion of patients with prior exon 20 inhibitor treatment and active brain metastases.

• Initial ESMO data showed confirmed systemic and brain responses, including in patients who failed approved therapies.

• Expansion cohorts underway for EGFR exon 20, HER2 exon 20, and atypical EGFR mutations, with data update expected in H1 2025.

• Two provisional phase II doses (80mg and 120mg) selected; registrational study could start in H2 2025 if data supports.

• Differentiation based on safety and CNS activity, addressing unmet needs in patients with brain metastases.

ORIC-944 clinical development and competitive landscape

• In-licensed from Mirati, ORIC-944 is an allosteric PRC2 inhibitor with favorable drug properties and long half-life.

• Early phase I data showed strong target engagement, safety, and synergy with AR inhibitors; now advancing into combination studies.

• Pfizer’s mevorametostat data in combination with enzalutamide is seen as validating for the PRC2 target, with ORIC-944 positioned closely behind in development.

• Combination studies with apalutamide and darolutamide started in H1 2024; flexibility to combine with enzalutamide as well.

• Focus remains on prostate cancer, but other tumor types are being evaluated for future expansion.